DOCSLIB.ORG

Winning Over Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

WINNING OVER CANCER AnnualAnnual Report Report2017 2017 1 CONTENTS During the last year, I have been overwhelmed by the outpouring of love and support that followed the news that my cancer had returned. Of course, it has been a personal challenge but OVERVIEW OUR COMMNUNITIES I feel privileged to be able to give hope to others Message from Olivia ............................................ 3 Equipment, facilities and services .............. 32 who are going through cancer. It’s a challenging and amazing journey that I have been through Chairman’s report ................................................ 4 T marks the spot .................................................34 before and I am winning over again! Year at a glance .................................................... 5 The synergy of circles ........................................36 I am grateful for and incredibly proud of the important work being done at the Olivia Directors’ report .................................................... 6 Clinician scientist fellowships ....................... 37 Newton-John Cancer Institute. It is hugely Collaborations and partnerships ................38 reassuring to know that scientists, doctors, OUR HIGHLIGHTS Students: the next generation .................... 40 volunteers and other healthcare practitioners are working around the clock to win over cancer Flicking the switch on Donors and supporters .....................................41 Message from and that they are helping so many people who colon cancer’s own killer ................................... 7 Amazing gift leaves a lasting come to the Centre for support. Reducing the costs of legacy for cancer research .............................43 our founding The ONJCRI holds a special place in my lung cancer misdiagnosis ................................. 8 heart in this regard. Medical research and Suppressing cancer cell corruption .............. 9 scientific endeavour run through my veins - OUR ORGANISATION champion, and although I chose a musical path, I am Rising to the challenge of lung cancer .... 10 Board of Directors ..............................................44 proud to come from a family of scientists, Olivia doctors and artists. Creativity is the magic Organisational chart ....................................... 46 that links science and the arts, and it’s OUR LABORATORIES COO’s report ........................................................ 47 Newton-John wonderful to know that so many smart, Cancer & Inflammation .................................... 14 creative young women and men are devoting Key financial results ...........................................48 their lives to find a cure, or to make cancer a Cancer Immunobiology .................................... 16 AO, OBE manageable disease. Translational Genomics & Epigenomics .... 18 SHARING OUR RESEARCH Thank you to all the scientists and staff at Tumour Targeting ................................................20 ONJCRI who are making such an important International presentations .......................... 49 contribution to the progress in this global Oncogenic Transcription .................................. 22 Seminars ..................................................................50 endeavour. And thank you to our many friends Cell Death & Survival ..........................................24 and supporters whose generosity is helping the ground-breaking research at the Institute. Metastasis Research ..........................................26 A SHOW OF SUPPORT Matrix Microenvironment Olivia Newton-John LOVE AND LIGHT & Metastasis ..........................................................28 Wellness Walk and Research Run ................51 Tumour Progression & Heterogeneity.........30 Front cover image: Dr Tom John is tackling the biggest cancer killer with translational research that combines Olivia laboratory work and clinical practice to find new hope for patients (full story on page 10). 2 3 YEAR AT A GLANCE 89 $26.9M Staff Secured external this model. The integration of laboratory bench funding and bedside helps refine our research, make new discoveries and create more targeted treatments for patients. Our researchers and clinicians were also involved in a wide variety of clinical cancer % trials, with Institute investigators leading 13 Clinician scientists 128 trials in 2017. (% of research staff) These trials give patients access to potential new treatments, such as immunotherapies 51% and targeted therapies. They are an integral Female part of our journey in finding more effective staff Chairman’s treatments. You can read the personal stories of two patients and their trial experiences Report in this report. ONJCRI’s collaborative power is backed by our partnerships, and we continued to build THE HON JOHN BRUMBY AO these relationships through the establishment CHAIRMAN OF THE BOARD NHRMC of a new ACRF Tumour Imaging Centre and the grant As each year passes, I continue to be inspired deepening of our ties with La Trobe University. success by the people, passion and perseverance at Most importantly, we have spent the year 25% rate ONJCRI, and I am truly privileged to be Chair giving hope to patients; there are people who will 25 of the Board. be with us tomorrow as a result of our efforts. PhD & Honours Our scientists and clinicians work tirelessly at I thank the members of the ONJCRI Board, students 128 the coalface of cancer care and at the cutting who freely donate their time and expertise to Clinical trials led by edge of research, clinical trials and technology. guide the Institute, and the Executive Officers who Institute investigators This makes the Institute a leader in the oversee the day-to-day business of the Institute. development of experimental and breakthrough And, lastly, I want to express my gratitude treatments for cancer of the brain, breast, bowel to the donors and supporters who bolster our and lung, as well as lymphoma and melanoma. quest to win over cancer. I trust that you will In 2017 the Institute continued to punch enjoy reading about our work in this report. above its weight with a unique formula that achieves results. Our clinicians and researchers work closely % 170 together to combine their laboratory work 29 Research and patient care, and we have established PhD collaborations clinician scientist fellowships to further enable THE HON JOHN BRUMBY AO students with medical training 130 ONJCRI scientific papers published 4 OUR HIGHLIGHTS FLICKING THE SWITCH ON COLON CANCER’S During 2017 ONJCRI increased the strength OWN KILLER and breadth of our science by recruiting new John estimates this diagnostic test could lead laboratory teams such as the Tumour Extending the life expectancy to the development of a tailored treatment for up Progression & Heterogeneity Laboratory. for colon cancer patients and to one in five patients with colon cancer, and that We received wide acclaim for our clinician would be significant progress given the limited scientists who developed better brain cancer improving their quality of life has treatment options for these patients. treatments, and the very sad news of Olivia’s driven Prof John Mariadason for “There are probably five or six treatments that returned breast cancer put our breast cancer the last two decades. are approved at the moment for colon cancer and dormancy research into sharp focus. often patients will be given all of those and yet Meanwhile, our ongoing work in lung, colon “When I started in the field, the life expectancy their cancers will still keep growing,” he says. and other gastrointestinal cancers, lymphoma was about 12 months for a patient with advanced “Our exciting finding needs to be tested in the and melanoma remained strong areas of focus colon cancer. I’ve seen that improve to about 30 clinic, but we have a way forward to safely test and achievement, both in the laboratory and months now,” says John, who leads the Oncogenic Directors’ a new treatment for patients with colon and at the bedside. Transcription Laboratory. other solid tumours, which is urgently needed.” Within our laboratory programs, we “I’ve also seen progress in the treatment of Report continued to develop new non-invasive blood other cancers that have been historically very tests to improve diagnosis and better monitor very difficult to manage. That has given me and PROF JONATHAN CEBON a patient’s response to cancer treatments. Our my colleagues around the globe the conviction disease-based research was complemented by MEDICAL DIRECTOR that we can and will achieve major breakthroughs our pursuit to better understand cell death and for colon cancer.” PROF MATTHIAS ERNST the interplay between cancer, inflammation John’s team is one step closer to that SCIENTIFIC DIRECTOR and immunity as processes important for many breakthrough with its latest research findings, types of cancers. which are part of a PhD being done by Janson Tse. We were recently asked to describe what makes The Institute could not succeed without Last year the team revealed that a class of drugs ONJCRI an exceptional medical research the diligent support of a dedicated Board of commonly used to halt the growth of leukemias institute. Our response? Aside from excellence, Directors and Scientific Advisory Committee, and lymphomas could be used to potentially creativity and effectiveness, it is our passion for our partnership with La Trobe University and target and kill colon cancer cells. clinical translation – a process of turning great the broader Austin Health
Recommended publications
  • Patterns, Paradoxes and Personalities Medical History Museum, University of Melbourne the Story of Cancer Is Complex and Extremely Personal

    Patterns, Paradoxes and Personalities Medical History Museum, University of Melbourne the Story of Cancer Is Complex and Extremely Personal

    THE cancer puzzle patterns, paradoxes and personalities Medical History Museum, University of Melbourne The story of cancer is complex and extremely personal. One in two Australian men and one in three Australian women will be diagnosed with cancer by the age of 85. For generations, doctors and researchers have been searching for remedies for this disease, which has long been shrouded in fear and dread. While surgery, radiotherapy and chemotherapy are still the main treatments, radically new approaches and technologies are emerging, together with a much more sophisticated understanding of the causes and very nature of cancer. Central to the story of cancer in Victoria has been the contribution of the University of Melbourne, in undertaking fundamental and applied research, developing treatments, training clinicians and scientists, educating the public, and advocating for change. Significant figures in the Melbourne Medical School, such as Professor Peter MacCallum, have helped build the infrastructure that underpins cancer services for the Victorian community. The cancer puzzle: Patterns, paradoxes and personalities explores the roles of individuals, public education campaigns and research efforts, as well as revealing patients’ insights through the work and writings of three contemporary artists who have cancer. the cancer puzzle PATTERNS, PARADOXES AND PERSONALITIES Edited by Jacqueline Healy Medical History Museum University of Melbourne Contents Foreword vii Published 2017 by the Medical History Museum, The exhibition The cancer puzzle: Patterns, paradoxes and personalities, Professor Mark Cook Faculty of Medicine, Dentistry and Health Sciences, curated by Dr Jacqueline Healy, was held at the Medical History University of Melbourne, Victoria, 3010, Australia Museum, University of Melbourne, from 1 August 2017 to Sponsor’s message ix 24 February 2018.
  • Therapeutic Options for Mucinous Ovarian Carcinoma

    Therapeutic Options for Mucinous Ovarian Carcinoma

    Edinburgh Research Explorer Therapeutic options for mucinous ovarian carcinoma Citation for published version: Gorringe, KL, Cheasley, D, Wakefield, MJ, Ryland, GL, Allan, PE, Alsop, K, Amarasinghe, KC, Ananda, S, Bowtell, DDL, Christie, M, Chiew, Y, Churchman, M, Defazio, A, Fereday, S, Gilks, CB, Gourley, C, Hadley, AM, Hendley, J, Hunter, SM, Kaufmann, SH, Kennedy, CJ, Köbel, M, Le Page, C, Li, J, Lupat, R, Mcnally, OM, Mcalpine, JN, Pyman, J, Rowley, SM, Salazar, C, Saunders, H, Semple, T, Stephens, AN, Thio, N, Torres, MC, Traficante, N, Zethoven, M, Antill, YC, Campbell, IG & Scott, CL 2020, 'Therapeutic options for mucinous ovarian carcinoma', Gynecologic Oncology, vol. 156, no. 3, pp. 552-560. https://doi.org/10.1016/j.ygyno.2019.12.015 Digital Object Identifier (DOI): 10.1016/j.ygyno.2019.12.015 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Gynecologic Oncology Publisher Rights Statement: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc- nd/4.0/).Contents lists available atScienceDirectGynecologic Oncologyjournal homepage:www.elsevier.com/locate/ygyno General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation.
  • The Early Work on the Discovery of the Function of the Thymus, an Interview with Jacques Miller

    The Early Work on the Discovery of the Function of the Thymus, an Interview with Jacques Miller

    Cell Death & Differentiation (2020) 27:396–401 https://doi.org/10.1038/s41418-019-0462-y Q&A The early work on the discovery of the function of the thymus, an interview with Jacques Miller Jacques Miller1 Published online: 5 December 2019 © The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare 2019. This article is published with open access This interview is part of a series of articles to mark the 25th anniversary of Cell Death and Differentiation. identified. Here, Cell Death and Differentiation asks Jac- ques Miller about his early work on thymus and T cells. CDD: Could you please describe your personal background, who were your parents, where were you born and what happened in your early years? My father and mother were both born in Paris in 1896. During the first World War (1914–1918), my father, Maurice Meunier, who spoke English fluently, acted as interpreter for the British troops who came to France. In 1919, he married and left with his new wife for China having found a job in a French bank in Peking (now known as Beijing). He spent some 22 years in China and Japan, eventually becoming Manager of the Franco-Chinese Bank in Shanghai. Besides English, he also spoke Spanish flu- ently, and learned Mandarin Chinese which he could write, and also Japanese which he wrote and spoke. In 1930, my mother returned to France by ship for health reasons. Finding that she was pregnant, she decided to have Fig. 1 Jacques (left), Gus Nossal (right) in 1967.
  • The Patients of the Bristol Lunatic Asylum in the Nineteenth Century 1861-1900

    The Patients of the Bristol Lunatic Asylum in the Nineteenth Century 1861-1900

    THE PATIENTS OF THE BRISTOL LUNATIC ASYLUM IN THE NINETEENTH CENTURY 1861-1900 PAUL TOBIA A thesis submitted in partial fulfilment of the requirements of the University of the West of England, Bristol for the degree of Doctor of Philosophy Faculty of Arts, Creative Industries and Education March 2017 Word Count 76,717 1 Abstract There is a wide and impressive historiography about the British lunatic asylums in the nineteenth century, the vast majority of which are concerned with their nature and significance. This study does not ignore such subjects but is primarily concerned with the patients of the Bristol Asylum. Who were they, what were their stories and how did they fare in the Asylum and how did that change over our period. It uses a distinct and varied methodology including a comprehensive database, compiled from the asylum records, of all the patients admitted in the nineteenth century. Using pivot tables to analyse the data we were able to produce reliable assessments of the range and nature of the patients admitted; dispelling some of the suggestions that they represented an underclass. We were also able to determine in what way the asylum changed and how the different medical superintendents altered the nature and ethos of the asylum. One of these results showed how the different superintendents had massively different diagnostic criteria. This effected the lives of the patients and illustrates the somewhat random nature of Victorian psychiatric diagnostics. The database was also the starting point for our research into the patients as individuals. Many aspects of life in the asylum can best be understood by looking at individual cases.
  • Golden Yearbook

    Golden Yearbook

    Golden Yearbook Golden Yearbook Stories from graduates of the 1930s to the 1960s Foreword from the Vice-Chancellor and Principal ���������������������������������������������������������5 Message from the Chancellor ��������������������������������7 — Timeline of significant events at the University of Sydney �������������������������������������8 — The 1930s The Great Depression ������������������������������������������ 13 Graduates of the 1930s ���������������������������������������� 14 — The 1940s Australia at war ��������������������������������������������������� 21 Graduates of the 1940s ����������������������������������������22 — The 1950s Populate or perish ���������������������������������������������� 47 Graduates of the 1950s ����������������������������������������48 — The 1960s Activism and protest ������������������������������������������155 Graduates of the 1960s ���������������������������������������156 — What will tomorrow bring? ��������������������������������� 247 The University of Sydney today ���������������������������248 — Index ����������������������������������������������������������������250 Glossary ����������������������������������������������������������� 252 Produced by Marketing and Communications, the University of Sydney, December 2016. Disclaimer: The content of this publication includes edited versions of original contributions by University of Sydney alumni and relevant associated content produced by the University. The views and opinions expressed are those of the alumni contributors and do
  • Innate Immunity and Dendritic Cells in Kidney Disease and the Nobel Prize

    Innate Immunity and Dendritic Cells in Kidney Disease and the Nobel Prize

    EDITORIALS www.jasn.org Innate Immunity and Dendritic nately, Janeway died in 2003 and was no longer eligible to receive the prize. Cells in Kidney Disease and the The discoveries of Hoffmann and Janeway alerted immu- nologists all over the world to the possibility of a new signal- Nobel Prize ing pathway, and in 1998, Bruce Beutler and colleagues at the † Howard Hughes Medical Institute in Dallas first identified Hans-Joachim Anders* and Christian Kurts TLR4 as recognizing bacterial endotoxin.5 Beutler’s approach *Medizinische Poliklinik, Klinikum der Universita¨t Mu¨ nchen-LMU, Campus Innenstadt, Munich, Germany; and †Institutes of Molecu- was as clever as simple. He took advantage of two well-known lar Medicine and Experimental Immunology (IMMEI), University lipopolysaccharide-resistant mouse strains to map the newly Clinic of Bonn, Bonn, Germany discovered loci of the Toll genes. In doing so, he realized that J Am Soc Nephrol 22: ●●●–●●●, 2011. endotoxin resistance was linked to loss-of-function muta- doi: 10.1681/ASN.2011100975 tions in the Tlr4 gene. Two more circumstances encouraged researchers from many disciplines to rush into this new area of science, pro- On December 10, 2011, the Nobel Prize for Physiology or ducing more than 18,000 related publications within the last Medicine will honor the work of Jules Hoffmann, Bruce 15 years: first, Tlr4 mutant mice as well as suitable immuno- Beutler, and Ralph Steinman for their landmark discoveries stimulatory compounds, now discovered as agonists for dis- in the field of immunology. This recognition brings wide at- tinct TLRs, became available at relatively low costs to every- tention to a paradigm shift in understanding how multicel- one, and second, Shizou Akira, in Osaka, produced null mice lular organisms sense and interpret their external and inter- for most TLRs and many other related genes, and did not nal environments in maintaining homeostasis or initiating hesitate to share them with collaborators and competitors.
  • Abstract Book Alfred Health Week Research Poster Display 23 – 27 October 2017

    Abstract Book Alfred Health Week Research Poster Display 23 – 27 October 2017

    Alfred Health Week Research Poster Display 23 – 27 October 2017 The Alfred Hospital ABSTRACT BOOK ALFRED HEALTH WEEK RESEARCH POSTER DISPLAY 23 – 27 OCTOBER 2017 RESEARCH DAY Tuesday, 24 October 2016, 12:00 PM – 1:00 PM AMREP Lecture Theatre 2017 KEYNOTE SPEAKER: The Hon. John Brumby AO Former Premier of Victoria, Chair, Foundation Committee, Global Health Alliance Melbourne; Faculty of Business and Economics, University of Melbourne “To the Bedside and Beyond: Medical Research and Victoria’s Future” 1 POSTER PRIZES Michael J Hall Memorial Prize for Respiratory Physiology Professor Daniel Czarny Prize for Allergy, Asthma and Clinical Immunology Research Lucy Battistel Prize for Allied Health Research Henrietta Law Memorial Prize for Allied Health Research Burnet Institute Prize for Infectious Diseases Research Monash Comprehensive Cancer Consortium Prize for Cancer Research Noel and Imelda Foster Prize for Cardiovascular Research Baker Heart and Diabetes Institute Prize for Cardiovascular Research Baker Heart and Diabetes Institute Prize for Diabetes Research Senior Medical Staff Prize for Basic Science/Laboratory-Based Research Senior Medical Staff Prizes for Clinical/Public Health Research Tony Charlton Prize for Cardiac Surgical Research Monash Alfred Psychiatry Research Centre Prize for Psychiatry Research The Greg Barclay Nursing Research Award The Senior Medical Staff Award 2 CONTENTS CATEGORY PAGE ALLERGY / ASTHMA / IMMUNITY 1. HOW DO THE PROXIMAL AND PERIPHERAL ASTHMATIC AIRWAYS RESPOND WHEN PROVOKED 15 DIRECTLY AND INDIRECTLY? Dharmakumara M, Stuart-Andrews C, Zubrinich C, Thompson B 2. ACINAR VENTILATION HETEROGENEITY IS INCREASED IN IDIOPATHIC PULMONARY FIBROSIS 15 (IPF) AND COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE) Ellis M, Prasad J, Westall G, Thompson B 3.
  • Genomic Analysis of Low‐Grade Serous Ovarian Carcinoma To

    Genomic Analysis of Low‐Grade Serous Ovarian Carcinoma To

    Journal of Pathology J Pathol 2020; 00: 000–000 ORIGINAL PAPER Published online 28 October 2020 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/path.5545 Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities Dane Cheasley1,2 , Abhimanyu Nigam1,2, Magnus Zethoven1,3, Sally Hunter2, Dariush Etemadmoghadam2, Timothy Semple4, Prue Allan5, Mark S Carey6, Marta L Fernandez6, Amy Dawson6, Martin Köbel7, David G Huntsman8, Cécile Le Page9 , Anne-Marie Mes-Masson9, Diane Provencher9, Neville Hacker10, Yunkai Gao1,2, David Bowtell11, Anna deFazio12, Kylie L Gorringe2† and Ian G Campbell1,2†* 1 Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia 3 Bioinformatics Consulting Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 4 Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 5 Department of Clinical Pathology, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, VIC, Australia 6 Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada 7 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada 8 Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada 9 Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM) and
  • Contact Us Pride from Down Under Jacques Miller

    Contact Us Pride from Down Under Jacques Miller

    ASI NEWS DECEMBER 2019 CONTACT US AUSTRALIAN AND NEW 15 29 ZEALAND SOCIETY FOR PRIDE FROM DOWN 49TH ASI ANNUAL IMMUNOLOGY INC. UNDER MEETING & BEST ASI ASI INC. SERETARIAT JACQUES MILLER RECEIVES POSTER HIGHLIGHT PO BOX 1371, 2019 LASKER AWARD AUCKLAND MITCHAM NORTH 3132 NEW ZEALAND PH: 03 8393 9388 immunology.org.au/contact-us CONTENTS ASI NEWSLETTER DECEMBER 2019 CONTENTS THE WEEK AFTER THANKSGIVING .................... 3 NZ Branch Report ................................................................27 Angelica Lau Ries Langley, NZ Councillor 2018 CTI PUBLICATION IT’S A WRAP FOR 2019! .......................................28 OF THE YEAR AWARD ............................................ 7 Stuart Mannering Biosketch - Harini de Silva (First Author) 49TH ASI ANNUAL MEETING 2020 ..................29 THE IUIS CORNER ................................................... 8 2018 BEST ASI POSTER WINNER ......................30 J. Alejandro Lopez, Susanne Heinzel, Menno van Sherly Maridana Zelm and Farzi Kordbacheh ASI POST-GRADUATE INTERNATIONAL ASI WINS THE IUIS BEST 2019 TRAVEL AWARD RECIPIENT .............................. 32 DOI CAMPAIGN AWARD ........................................11 European Cell Death Organization, Gabriela Khoury Georgia Atkin-Smith NEWS FROM FIMSA ..............................................12 ASI POST-GRADUATE INTERNATIONAL Joanna Groom TRAVEL AWARD RECIPIENT ..............................34 WOMEN’S INITIATIVE NEWS ..............................14 The Joint Meeting of the German Society for Kylie Quinn Immunology
  • 2010-2011 Annual Report

    2010-2011 Annual Report

    Annual Report 2010-2011 Mastery of disease through discovery | www.wehi.edu.au Contents 1 About the institute 3 Director’s and Chairman’s report 5 Discovery 8 Cancer and Haematology 10 Stem Cells and Cancer 12 Molecular Genetics of Cancer 14 Chemical Biology 16 Molecular Medicine 18 Structural Biology 20 Bioinformatics 22 Infection and Immunity 24 Immunology The Walter and Eliza Hall Institute 26 Autoimmunity and Transplantation of Medical Research 28 Cell Signalling and Cell Death 1G Royal Parade 30 Inflammation Parkville Victoria 3052 Australia Telephone: (+61 3) 9345 2555 32 Molecular Immunology Facsimile: (+61 3) 9347 0852 34 Publications WEHI Biotechnology Centre 36 Awards 4 Research Avenue 37 Translation La Trobe R&D Park Bundoora Victoria 3086 Australia Translating our research 38 Telephone: (+61 3) 9345 2200 40 Developing our research Facsimile: (+61 3) 9345 2211 42 Patents www.wehi.edu.au www.facebook.com/WEHIresearch 43 Education www.twitter.com/WEHI_research 46 2010-11 graduates ABN 12 004 251 423 47 Seminars Acknowledgements 48 Institute awards Produced by the institute’s Community Relations department 49 Engagement Managing editor: Penny Fannin Editor: Liz Williams 51 Strategic partners Writers: Liz Williams, Vanessa Solomon and Julie Tester 52 Scientific and medical community Design and production: Simon Taplin Photography: Czesia Markiewicz and Cameron Wells 54 Public engagement 57 Engagement with schools Cover image 58 Donor and bequestor engagement Art in Science finalist 2010 Vessel webs 59 Sustainability Dr Leigh Coultas, Cancer and Haematology division 60 The Board This image shows the delicate intricacy in the developing eye of a transient population of web-like blood vessels.
  • Impact of an Allied Health Prehabilitation Service for Haematologic Patients Receiving High Dose Chemotherapy in a Large Cancer Centre

    Impact of an Allied Health Prehabilitation Service for Haematologic Patients Receiving High Dose Chemotherapy in a Large Cancer Centre

    Impact of an Allied Health Prehabilitation Service for Haematologic Patients Receiving High Dose Chemotherapy in A Large Cancer Centre Jessica Crowe ( [email protected] ) Peter MacCallum Cancer Centre https://orcid.org/0000-0002-7913-0013 Jill Francis The University of Melbourne Melbourne School of Health Sciences Lara Edbrooke Peter MacCallum Cancer Centre Jenelle Loeliger Peter MacCallum Cancer Centre Trish Joyce Peter MacCallum Cancer Centre Christina Prickett Peter MacCallum Cancer Centre Alicia Martin Peter MacCallum Cancer Centre Amit Khot Peter MacCallum Cancer Centre Linda Denehy Melbourne School of Health Sciences: The University of Melbourne Melbourne School of Health Sciences The Centre for Prehabilitation and Peri-operative Care Peter MacCallum Cancer Centre Research Article Keywords: prehabilitation, implementation, allied health, autologous stem cell transplant, high dose chemotherapy. Posted Date: June 7th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-447123/v1 Page 1/23 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/23 Abstract Purpose To evaluate the impact of routine multidisciplinary allied health prehabilitation care in haematologic cancer patients receiving high-dose chemotherapy with autologous stem cell transplant (AuSCT). Methods In a tertiary cancer centre, 12-months of prospectively collected data was retrospectively analysed. Patients were referred to the service for individualised exercise prescription, nutrition intervention and, if indicated through screening, psychological intervention. Impact and operational success were investigated based on the RE-AIM framework: patient uptake of the service and sample representativeness (Reach); Effectiveness in terms of changes in outcomes from initial to pre-transplant assessment; Adoption of the service by key stakeholders; delity of the prescribed exercise program (Implementation); and the extent to which the service had become part of routine standard care (Maintenance).
  • Tumour Mutation Status and Sites of Metastasis in Patients with Cutaneous Melanoma

    Tumour Mutation Status and Sites of Metastasis in Patients with Cutaneous Melanoma

    FULL PAPER British Journal of Cancer (2017) 117, 1026–1035 | doi: 10.1038/bjc.2017.254 Keywords: cutaneous melanoma; melanoma; BRAF mutation; mutation status; metastasis; sentinel lymph node biopsy Tumour mutation status and sites of metastasis in patients with cutaneous melanoma Nikki R Adler*,1,2, Rory Wolfe2, John W Kelly1, Andrew Haydon1,3, Grant A McArthur4,5, Catriona A McLean1,6 and Victoria J Mar1,2,7 1Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria 3004, Australia; 2School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia; 3Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria 3004, Australia; 4Divisions of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia; 5Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3000, Australia; 6Department of Anatomical Pathology, Alfred Hospital, Melbourne, Victoria 3004, Australia and 7Skin and Cancer Foundation, Carlton, Victoria 3053, Australia Background: Cutaneous melanoma can metastasise haematogenously and/or lymphogenously to form satellite/in-transit, lymph node or distant metastasis. This study aimed to determine if BRAF and NRAS mutant and wild-type tumours differ in their site of first tumour metastasis and anatomical metastatic pathway. Methods: Prospective cohort of patients with a histologically confirmed primary cutaneous melanoma at three tertiary referral centres in Melbourne, Australia from 2010 to 2015. Multinomial regression determined clinical, histological and mutational factors associated with the site of first metastasis and metastatic pathway. Results: Of 1048 patients, 306 (29%) developed metastasis over a median 4.7 year follow-up period. 73 (24%), 192 (63%) and 41 (13%) developed distant, regional lymph node and satellite/in-transit metastasis as the first site of metastasis, respectively.